Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd. has acknowledged the resignation of Prateek Gupta (SVP & Head – Technical Development), effective at the close of business hours on May 15, 2026. The company submitted the acknowledgement copy of the resignation letter to the Stock Exchanges, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resignation was initially intimated on May 13, 2026.

Onesource Specialty Pharma Ltd has received in-principle approval from the Government of Karnataka for its Unit-II expansion project under the Karnataka Industrial Policy (KIP) 2025–30. The approval, granted on May 12, 2026, follows the company's proposal for investment in expanding its Unit II facility at Obadenahalli, considered during the 67th State High Level Clearance Committee (SHLCC) meeting on April 13, 2026. This expansion aims to enhance manufacturing capacities for servicing global partners and represents a significant step in the company's growth strategy.

Onesource Specialty Pharma Ltd announced its FY26 results, reporting revenues of ₹14,216 million and EBITDA of ₹3,042 million. Q4FY26 revenues stood at ₹4,282 million, up 47% QoQ, with EBITDA at ₹919 million, a 5x+ increase QoQ. The company reaffirmed its FY28 guidance of ~$400 million in organic revenue with ~40% EBITDA margin. Strong Q4 performance was driven by broad business momentum and India semaglutide launches. Adjusted PAT for FY26 was ₹739 million.

Onesource Specialty Pharma Ltd has decided not to pursue the composite scheme of arrangement and amalgamation (merger by absorption) with Steriscience Specialities Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, and Strides Pharma Services Private Limited in its current form. The decision was made by the Board of Directors after deliberation, citing the best interest of all stakeholders. The company plans to revisit the transaction after the successful delivery of the respective companies’ FY28 guidance.

Onesource Specialty Pharma Ltd has appointed BSR & Co. LLP as the statutory auditors of the company for a term of five consecutive years, starting from the conclusion of the 19th Annual General Meeting until the conclusion of the 24th AGM. This appointment is in place of Deloitte Haskins & Sells, whose term is ending. The decision was made during a board meeting held on May 13, 2026, where the audited financial results for the year ended March 31, 2026, were also approved.

Onesource Specialty Pharma Ltd announced the resignation of Prateek Gupta (SVP & Head – Technical Development), a Senior Management Personnel (SMP), effective May 13, 2026. The company has disclosed this information pursuant to Regulation 30 of the SEBI Listing Regulations.

Onesource Specialty Pharma Ltd's board approved the standalone and consolidated financial results for the quarter and year ended March 31, 2026, in its meeting held on May 13, 2026. The board also approved the appointment of B S R & Co LLP as the statutory auditors for a term of five years, replacing Deloitte Haskins & Sells. An unmodified opinion was issued in the Auditors’ Report for the financial year ended March 31, 2026.

Onesource Specialty Pharma Ltd has scheduled a Board of Directors meeting on May 13, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The trading window for designated persons is closed from April 1, 2026, and will open 48 hours after the dissemination of the financial results.

OneSource Specialty Pharma Ltd's partner, Orbicular, along with its Canadian front-end partner, received approval from Health Canada for a generic version of Ozempic® (semaglutide injection). This marks the second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in one of the world’s most significant semaglutide markets. OneSource supported the program as the manufacturing partner, providing end-to-end manufacturing capabilities for the Canadian filing. Commercial supply will be supported from OneSource’s US FDA-approved flagship facility in Bengaluru.

OneSource Specialty Pharma Limited announced that its partner, Dr. Reddy’s Laboratories Ltd., has received Health Canada approval for Semaglutide Injection, a generic version of Ozempic®. OneSource serves as the CDMO partner for this program, providing scale-up and commercial manufacturing support from its US-FDA approved facility in Bengaluru. This approval is expected to strengthen the collaboration between Dr. Reddy’s expertise in peptide development and OneSource’s CDMO capabilities, ensuring reliable and scalable commercial supply.